INDV
NASDAQ
US
Indivior Pharmaceuticals, Inc. - Common Stock
$30.47
▼ $-0.18
(-0.59%)
Vol 2.1M
10
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$4.5B
P/E
35.8
ROE
159.1%
Margin
10.6%
D/E
2790.00
Beta
4.47
52W
$8–$38
Wall Street Consensus
13 analysts · Apr 20264
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
92.3%
Buy Rating
Price Chart
Similar Stocks
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34.5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76.6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
LQDA
Liquidia Corp
$3.0B
TARS
Tarsus Pharmaceuticals Inc
$3.5B
SUPN
Supernus Pharmaceuticals Inc
$2.8B
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.69 | $0.82 | +$0.13 |
| Sep 2025 | $0.42 | $0.72 | +$0.30 |
| Jun 2025 | $0.27 | $0.51 | +$0.24 |
| Mar 2025 | $0.24 | $0.41 | +$0.17 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $299.0M | $266.0M | $302.0M | $314.0M | $358.0M |
| Net Income | — | $59.0M | $47.0M | $18.0M | $42.0M | $102.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | 135.4% | 135.4% | 135.4% | 159.1% | 159.1% |
| P/E (TTM) | 12.88 | — | — | — | 33.96 | 35.84 |
| Net Margin | 6.0% | -4.4% | -4.4% | -4.4% | 10.6% | 10.6% |
| Gross Margin | 82.8% | 147.9% | 147.9% | 147.9% | 85.5% | 85.5% |
| D/E Ratio | — | 2790.00 | 2790.00 | 2790.00 | 2790.00 | 2790.00 |
| Current Ratio | 0.90 | 0.88 | 0.88 | 0.88 | 0.96 | 0.96 |
Key Ratios
ROA (TTM)
9.0%
P/S (TTM)
3.80
P/B
49.6
EPS (TTM)
$0.98
Rev Growth 3Y
+14.5%
52W High
$38.00
52W Low
$7.62
$7.62
52-Week Range
$38.00
Financial Health
Free Cash Flow
-$245.0M
Net Debt
$156.0M
Cash
$195.0M
Total Debt
$351.0M
As of Dec 31, 2025
How does INDV compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
INDV valuation vs Pharmaceuticals peers
P/E ratio
35.8
▲
17%
above
peers
(30.7)
vs Peers
vs Industry
Undervalued
P/S ratio
3.8
▼
44%
below
peers
(6.7)
vs Peers
vs Industry
Undervalued
P/B ratio
49.6
▲
850%
above
peers
(5.2)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
INDV profitability vs Pharmaceuticals peers
ROE
159.1%
▲
710%
above
peers
(-26.1%)
vs Peers
vs Industry
Top tier
Net margin
10.6%
▲
830%
above
peers
(-1.5%)
vs Peers
vs Industry
Below avg
Gross margin
85.5%
▼
4%
below
peers
(88.9%)
vs Peers
vs Industry
Weak
ROA
9.0%
▲
195%
above
peers
(-9.5%)
vs Peers
vs Industry
Top tier
INDV financial health vs Pharmaceuticals peers
D/E ratio
2790.0
▲
10101%
above
peers
(27.4)
vs Peers
vs Industry
High debt
Current ratio
1.0
▼
73%
below
peers
(3.5)
vs Peers
vs Industry
Low liquidity
Beta
4.5
▲
658%
above
peers
(0.6)
vs Peers
vs Industry
More volatile
INDV fundamentals radar
INDV
Peer median
Industry
INDV profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
INDV vs peers: key metrics
Related Signals
Latest News
No related news yet